3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
56
Lymphoma, Large B-Cell, Diffuse
55
Lymphoma, Follicular
48
Lymphoma
47
Leukemia, Lymphocytic, Chronic, B-Cell
45
Lymphoma, Mantle-Cell
41
Lymphoma, B-Cell, Marginal Zone
24
Lymphoma, B-Cell
22
Waldenstrom Macroglobulinemia
17
Hodgkin Disease
16
Burkitt Lymphoma
16
Leukemia
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Recurrence
10
Lymphoma, Large-Cell, Immunoblastic
9
Neoplasms
7
Multiple Myeloma
6
Myelodysplastic Syndromes
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, Extranodal NK-T-Cell
4
Leukemia, Hairy Cell
4
Intraocular Lymphoma
4
Hematologic Neoplasms
4
Sezary Syndrome
3
Mycosis Fungoides
3
Lymphoma, T-Cell
3
Lymphoma, Primary Effusion
3
Immunoblastic Lymphadenopathy
3
Interventions
ibrutinib
2
Bortezomib
2
ponatinib
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
durvalumab
1
blinatumomab
1
Rituximab
1
Lenalidomide
1
KW-2478
1
Hsp90 inhibitor KU757
1
Cyclophosphamide
1
CA-4948
1
Bendamustine Hydrochloride
1
ARQ531
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Immunoproliferative Disorders
×
Rituximab
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts